cardiovascularКардиоваскулярная терапия и профилактикаCardiovascular Therapy and Prevention1728-88002619-0125«SILICEA-POLIGRAF» LLCcardiovascular-1514Research ArticleМНЕНИЕ ПО ПРОБЛЕМЕOPINION ON A PROBLEMМетоды оценки функционального состояния почек при артериальной гипертонии: клиническое значение и практическое применениеMethods of renal function assessment in arterial hypertension: the clinical value and practical implementationКобалаваЖ. Д.KobalavaZh. D.

Заведующая кафедрой пропедевтики внутренних болезней.

Москва

Moscow

КотовскаяЮ. В.KotovskayaYu. V.

Профессор кафедры.

Москва, тел.: 8 (926) 214-02-33

Moscow

Kotovskaya@bk.ruВиллевальдеС. В.VillewaldeS. V.

Доцент кафедры.

Москва

Moscow

Российский университет дружбы народовRussian University of People’s Friendship200920122009866166Copyright © Кобалава Ж.Д., Котовская Ю.В., Виллевальде С.В., 20092009Кобалава Ж.Д., Котовская Ю.В., Виллевальде С.В.Kobalava Z.D., Kotovskaya Y.V., Villewalde S.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://cardiovascular.elpub.ru/jour/article/view/1514

Обзор литературы посвящен проблеме современных методов выявления доклинического поражения почек. Широкая распространенность нарушений функции почек при сердечно-сосудистых заболеваниях (ССЗ), их роль в стратификации риска развития сердечно-сосудистых и почечных осложнений, возможность предотвращения осложнений соответствующими терапевтическими вмешательствами делают актуальным поиск методов, позволяющих выявить нарушение функции почек на доклинических стадиях. Повышение креатинина сыворотки, снижение клиренса креатинина или расчетной скорости клубочковой фильтрации (СКФ), микроальбуминурия обладают независимым прогностическим значением в отношении сердечно-сосудистой заболеваемости и смертности. У всех пациентов с артериальной гипертонией необходимо оценивать СКФ и определять экскрецию белка с мочой. Актуален поиск нефропротективных стратегий, направленных на замедление прогрессирования протеинурии и снижение СКФ.

This literature review is focused on the modern diagnostic methods in pre-clinical renal pathology. The wide prevalence of renal dysfunction in cardiovascular disease (CVD), its role in the stratification of cardiovascular and renal complication risk, and the potential for medical prevention of these complications justify the search for the methods diagnosing pre-clinical renal pathology. Increased serum creatinine, reduced creatinine clearance or estimated glomerular filtration rate (GFR), and microalbuminuria are independent predictors of cardiovascular morbidity and mortality. In all patients with arterial hypertension, estimated GFR and urinary albumin excretion should be assessed. Nephroprotective strategies, delaying progression of proteinuria and GFR reduction, should be identified.

сердечно-сосудистый рискскорость клубочковой фильтрациимикроальбуминуриянефропротекцияcardiovascular riskglomerular filtration ratemicroalbuminurianephroprotectionReferencesМухин Н.А., Моисеев В.С. Кардиоренальные соотношения и риск сердечно-сосудистых заболеваний. Вестник РАМН 2003; 11: 50-5.Мухин Н.А., Моисеев В.С. Кардиоренальные соотношения и риск сердечно-сосудистых заболеваний. Вестник РАМН 2003; 11: 50-5.Мухин НА, Моисеев ВС, Кобалава ЖД и др. Кардиоренальные взаимодействия: клиническое значение и роль в патогенезе заболеваний сердечно-сосудистой системы и почек. Тер архив 2004; 6: 39-46.Мухин НА, Моисеев ВС, Кобалава ЖД и др. Кардиоренальные взаимодействия: клиническое значение и роль в патогенезе заболеваний сердечно-сосудистой системы и почек. Тер архив 2004; 6: 39-46.Мухин Н.А., Фомин В.В.,МоисеевС.В. Микроальбуминурия — универсальный маркер неблагоприятного прогноза. Клин мед 2008; 11: 4-9.Мухин Н.А., Фомин В.В.,МоисеевС.В. Микроальбуминурия — универсальный маркер неблагоприятного прогноза. Клин мед 2008; 11: 4-9.Мухин Н.А. Снижение скорости клубочковой фильтрации — общепопулярный маркер неблагоприятного прогноза. Тер архив 2007; 6: 5-10.Мухин Н.А. Снижение скорости клубочковой фильтрации — общепопулярный маркер неблагоприятного прогноза. Тер архив 2007; 6: 5-10.Anavekar NS, McMurray JJ, Velazquez EJ et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004; 351: 1285-95.Anavekar NS, McMurray JJ, Velazquez EJ et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004; 351: 1285-95.Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-305.Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-305.Ruilope LM, Salvetti A., Jamerson K. et al. Renal function and intensive lowering of blood pressure in hypertensive participants of the Hypertension Optimal Treatment (HOT) study. J Am Soc Nephrol 2001; 12: 218-25.Ruilope LM, Salvetti A., Jamerson K. et al. Renal function and intensive lowering of blood pressure in hypertensive participants of the Hypertension Optimal Treatment (HOT) study. J Am Soc Nephrol 2001; 12: 218-25.De Leeuw PW, Ruilope LM, Palmer CR, et al. Clinical significance of renal function in hypertensive patients at high risk: results from the INSIGHT trial. Arch Intern Med 2004; 164: 2459-64.De Leeuw PW, Ruilope LM, Palmer CR, et al. Clinical significance of renal function in hypertensive patients at high risk: results from the INSIGHT trial. Arch Intern Med 2004; 164: 2459-64.Функциональное состояние почек и прогнозирование сердечно-сосудистого риска. Кардиоваск тер профил 2008; 7(6): Приложение 3: 1-20.Функциональное состояние почек и прогнозирование сердечно-сосудистого риска. Кардиоваск тер профил 2008; 7(6): Приложение 3: 1-20.Диагностика и лечение артериальной гипертензии. Рекомендации РМОАГ и ВНОК. Кардиоваск тер профил 2008; 7(6): Приложение 2: 1-16.Диагностика и лечение артериальной гипертензии. Рекомендации РМОАГ и ВНОК. Кардиоваск тер профил 2008; 7(6): Приложение 2: 1-16.2007 Guidelines for the Management of Arterial Hypertension The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105-87.2007 Guidelines for the Management of Arterial Hypertension The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105-87.K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004; 43 (5 Suppl 1): S1-290.K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004; 43 (5 Suppl 1): S1-290.Levey AS, Greene T, Kusek JW, Beck GJ. MDRD Study Group. A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol 2000; 11: 155A.Levey AS, Greene T, Kusek JW, Beck GJ. MDRD Study Group. A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol 2000; 11: 155A.Lin J, Knight EL, Hogan ML, Singh AK. A comparison of prediction equations for estimating glomerular filtration rate in adults without kidney disease. J Am Soc Nephrol 2003; 14: 2573¬80.Lin J, Knight EL, Hogan ML, Singh AK. A comparison of prediction equations for estimating glomerular filtration rate in adults without kidney disease. J Am Soc Nephrol 2003; 14: 2573¬80.Moe S, Drueke T, Cunningham J, et al. Kidney Disease: Improving Global Outcomes (KDIGO). Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2005; 67: 2089-100.Moe S, Drueke T, Cunningham J, et al. Kidney Disease: Improving Global Outcomes (KDIGO). Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2005; 67: 2089-100.Rule AD, Larson TS, Bergstralh EJ, et al. Using serum creatinine to estimate glomerular filtration rate: accuracy in good health and in chronic kidney disease. Ann Intern Med 2004; 141: 929-37.Rule AD, Larson TS, Bergstralh EJ, et al. Using serum creatinine to estimate glomerular filtration rate: accuracy in good health and in chronic kidney disease. Ann Intern Med 2004; 141: 929-37.Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.Hoek FJ, Kemperman FAW, Krediet RT. A comparison between cystatin C, plasma creatinine and the Cockcroft and Gault formula for the estimation of glomerular filtration rate. Nephrol Dial Transplant 2003; 18: 2024-31.Hoek FJ, Kemperman FAW, Krediet RT. A comparison between cystatin C, plasma creatinine and the Cockcroft and Gault formula for the estimation of glomerular filtration rate. Nephrol Dial Transplant 2003; 18: 2024-31.Levin A. Cystatin C, serum creatinine, and estimates of kidney function: searching for better measures of kidney function and cardiovascular risk. Ann Intern Med 2005; 142: 586-8.Levin A. Cystatin C, serum creatinine, and estimates of kidney function: searching for better measures of kidney function and cardiovascular risk. Ann Intern Med 2005; 142: 586-8.Seliger SL, DeFilippi C. Role of Cystatin C as a Marker of Renal Function and Cardiovascular Risk Medscape 26 Oct 2006. www.medscape.comSeliger SL, DeFilippi C. Role of Cystatin C as a Marker of Renal Function and Cardiovascular Risk Medscape 26 Oct 2006. www.medscape.comDharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis 2002; 40: 221-6.Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis 2002; 40: 221-6.Sarnak MJ, Katz R, Stehman-Breen CO, et al. Cardiovascular Health Study. Cystatin C concentration as a risk factor for heart failure in older adults. Ann Intern Med 2005; 142: 497-505.Sarnak MJ, Katz R, Stehman-Breen CO, et al. Cardiovascular Health Study. Cystatin C concentration as a risk factor for heart failure in older adults. Ann Intern Med 2005; 142: 497-505.Knight EL, Verhave JC, Spiegelman D, et al. Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int 2004; 65: 1416-21.Knight EL, Verhave JC, Spiegelman D, et al. Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int 2004; 65: 1416-21.Hillege HL, Fidler V, Diercks GF, et al. Prevention of Renal and Vascular End Stage Disease (PREVEND) Study Group. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002; 106: 1777-82.Hillege HL, Fidler V, Diercks GF, et al. Prevention of Renal and Vascular End Stage Disease (PREVEND) Study Group. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002; 106: 1777-82.Arnlov J, Evans JC, Meigs JB, et al. Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study. Circulation 2005; 112: 969-75.Arnlov J, Evans JC, Meigs JB, et al. Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study. Circulation 2005; 112: 969-75.Redon J, Williams B. Microalbuminuria in essential hypertension: redefining the threshold. J Hypertens 2002; 20: 353-5.Redon J, Williams B. Microalbuminuria in essential hypertension: redefining the threshold. J Hypertens 2002; 20: 353-5.Jerums C, Premaratne E, Panagiotopoulos S, et al. New and old markers of progression of diabetic nephropathy. Diabetes research and clinical practice 2008; 82 (Suppl 1): S30-7.Jerums C, Premaratne E, Panagiotopoulos S, et al. New and old markers of progression of diabetic nephropathy. Diabetes research and clinical practice 2008; 82 (Suppl 1): S30-7.MacIsaac RJ, Jerums G. Albuminuric and non-albuminuric pathways to renal impairment in diabetes. Minerva Endocrinol 2005; 30(3): 161-77.MacIsaac RJ, Jerums G. Albuminuric and non-albuminuric pathways to renal impairment in diabetes. Minerva Endocrinol 2005; 30(3): 161-77.MacIsaac RJ, Tsalamandris C, Panagiotopoulos S, et al. Nonalbuminuric renal insufficiency in type 2 diabetes. Diabetes Care 2004; 27: 195-200.MacIsaac RJ, Tsalamandris C, Panagiotopoulos S, et al. Nonalbuminuric renal insufficiency in type 2 diabetes. Diabetes Care 2004; 27: 195-200.Ruggenenti P, Fassi A, Bruno S. Preventing Microalbuminuria in Type 2 Diabetes. NEJM 2004; 351(19): 1941-51.Ruggenenti P, Fassi A, Bruno S. Preventing Microalbuminuria in Type 2 Diabetes. NEJM 2004; 351(19): 1941-51.

The authors declare that there are no conflicts of interest present.